Showing results (1501-1510 of 1,523) with videos related to
Sort By:
Pageof 153
European Journal of Medical Research|March 16, 2025
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in TaiwanKuan-Chieh Tu, Wei-Ting Chang, Hui-Wen Lin, et al.Chinese Medical Journal|April 12, 2012
A prospective study to evaluate the efficacy of an intracardiac electrogram-based atrioventricular and interventricular intervals optimization method in cardiac resynchronization therapyWei Hua, Dong-Mei Wang, Lin Cai, et al.Journal for Immunotherapy of Cancer|January 6, 2025
GP73 reinforces cytotoxic T-cell function by regulating HIF-1α and increasing antitumor efficacyJialong Liu, Chao Feng, Ruzhou Zhao, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 17, 2022
2022 Taiwan lipid guidelines for primary preventionPo-Hsun Huang, Ya-Wen Lu, Yi-Lin Tsai, et al.Journal of Synchrotron Radiation|December 18, 2025
Development of arrival-time diagnostic tool for X-ray pump-probe experiments at Shanghai Soft X-ray Free Electron LaserZhi Qiao, Jiadong Fan, Zichen Gao, et al.Oral Oncology|May 1, 2018
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinomaMei Lin, Rui You, You-Ping Liu, et al.Physical Review Letters|March 12, 2021
Self-Amplification of Coherent Energy Modulation in Seeded Free-Electron LasersJiawei Yan, Zhangfeng Gao, Zheng Qi, et al.Biomedical and Environmental Sciences : BES|April 7, 2024
Development of a High-throughput Sequencing Platform for Detection of Viral Encephalitis Pathogens Based on Amplicon SequencingYa Li Zhang, Wen Zhe Su, Rui Chen Wang, et al.Theranostics|July 26, 2017
Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-upRui You, Yi-Jun Hua, You-Ping Liu, et al.International Journal of Cancer|June 4, 2017
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinomaRui You, Rui Sun, Yi-Jun Hua, et al.Pageof 153